Recent Applications of mRNA-Based Technology for Disease Therapy

Abstract

The success of COVID-19 mRNA vaccines has established mRNA as a powerful therapeutic platform. Key advantages of mRNA drugs include transient expression, rapid scalability, and universal protein-encoding capability. This review focuses on the application of mRNA therapies across a broad spectrum of diseases, including cancer, infectious diseases, genetic disorders, autoimmune diseases, and cardiovascular conditions. It systematically summarizes the latest progress in mRNA drug development, covering three major therapeutic paradigms: mRNA vaccines, protein replacement therapy, and mRNA-based gene editing. Emerging approaches, such as artificial intelligence tools for mRNA therapeutic design and advanced delivery systems, are also discussed. By integrating foundational mechanisms, engineering strategies, and translational examples, this review provides a comprehensive overview of the current landscape and future directions of mRNA-based therapeutics.

Keywords

mRNA therapeutics / mRNA vaccines / Protein replacement therapy / Gene editing / Lipid nanoparticles

References

[1] Rohner E, Yang R, Foo KS, Goedel A, Chien KR . Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 2022, 40, 1586-1600. DOI: 10.1038/s41587-022-01491-z

[2] Chaudhary N, Weissman D, Whitehead KA . mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. Nat. Rev. Drug Discov. 2021, 20, 817-838. DOI: 10.1038/s41573-021-00283-5

[3] Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 2025, 647, 488-497. DOI: 10.1038/s41586-025-09655-y

[4] Sayour EJ, Boczkowski D, Mitchell DA, Nair SK . Cancer mRNA vaccines: Clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 2024, 21, 489-500. DOI: 10.1038/s41571-024-00902-1

[5] Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: Looking beyond COVID-19 vaccines. Lancet 2024, 403, 1192-1204. DOI: 10.1016/S0140-6736(23)02444-3

[6] Cullis PR, Felgner PL . The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 2024, 23, 709-722. DOI: 10.1038/s41573-024-00977-6

[7] Dimitriadis GJ . Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 1978, 274, 923-924. DOI: 10.1038/274923a0

[8] Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo . Science 1990, 247, 1465-1468. DOI: 10.1126/science.1690918

[9] Shi Y, Shi M, Wang Y, You J . Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct. Target. Ther. 2024, 9, 322. DOI: 10.1038/s41392-024-02002-z

[10] Eygeris Y, Gupta M, Kim J, Sahay G . Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res. 2022, 55, 2-12. DOI: 10.1021/acs.accounts.1c00544

[11] Xiao Y, Tang Z, Huang X, Chen W, Zhou J, Liu H, et al. Emerging mRNA technologies: Delivery strategies and biomedical applications. Chem. Soc. Rev. 2022, 51, 3828-3845. DOI: 10.1039/D1CS00617G

[12] Joshi R, Sharma S, Kapoor DU, Prajapati BG, Huanbutta K, Sriamornsak P . mRNA-based therapeutics: Advances in drug delivery, comparative innovations, and biomedical applications. Mol. Pharm. 2026, 23, 583-621. DOI: 10.1021/acs.molpharmaceut.5c00774

[13] Guasp P, Reiche C, Sethna Z, Balachandran VP . RNA vaccines for cancer: Principles to practice. Cancer Cell 2024, 42, 1163-1184. DOI: 10.1016/j.ccell.2024.05.005

[14] Yaremenko AV, Khan MM, Zhen X, Tang Y, Tao W . Clinical advances of mRNA vaccines for cancer immunotherapy. Med 2025, 6, 100562. DOI: 10.1016/j.medj.2024.11.015

[15] Le T, Sun C, Chang J, Zhang G, Yin X. mRNA vaccine development for emerging animal and zoonotic diseases. Viruses 2022, 14, 401. DOI: 10.3390/v14020401

[16] Pardi N, Hogan MJ, Porter FW, Weissman D . mRNA vaccines-A new era in vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261-279. DOI: 10.1038/nrd.2017.243

[17] Jiang Z, Xu Y, Du G, Sun X . Emerging advances in delivery systems for mRNA cancer vaccines. J. Control. Release 2024, 370, 287-301. DOI: 10.1016/j.jconrel.2024.04.039

[18] Sun X, Setrerrahmane S, Li C, Hu J, Xu H . Nucleic acid drugs: Recent progress and future perspectives. Signal Transduct. Target. Ther. 2024, 9, 316. DOI: 10.1038/s41392-024-02035-4

[19] Karikó K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23, 165-175. DOI: 10.1016/j.immuni.2005.06.008

[20] Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 2008, 16, 1833-1840. DOI: 10.1038/mt.2008.200

[21] Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 2022, 7, 94. DOI: 10.1038/s41392-022-00950-y

[22] Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Investig. 2002, 109, 409-417. DOI: 10.1172/JCI14364

[23] Eli G, David B, Smita KN . The quest for mRNA vaccines. Nucleic Acid Ther. 2022, 32, 449-456. DOI: 10.1089/nat.2021.0103

[24] Blass E, Ott PA . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 2021, 18, 215-229. DOI: 10.1038/s41571-020-00460-2

[25] Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, et al. COVID-19 vaccine development: Milestones, lessons and prospects. Signal Transduct. Target. Ther. 2022, 7, 146. DOI: 10.1038/s41392-022-00996-y

[26] Sun S, Liu L, Zhang J, Sun L, Shu W, Yang Z, et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: Advances, mechanisms, and perspectives. J. Hematol. Oncol. 2025, 18, 84. DOI: 10.1186/s13045-025-01732-z

[27] Garzia I, Nocchi L, Avalle L, Troise F, Leoni G, Seclì L, et al. Tumor burden dictates the neoantigen features required to generate an effective cancer vaccine. Cancer Immunol. Res. 2024, 12, 440-452. DOI: 10.1158/2326-6066.CIR-23-0609

[28] Lichtenegger FS, Schnorfeil FM, Rothe M, Deiser K, Altmann T, Bücklein VL, et al. Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: Results of a phase I trial. Clin. Transl. Immunol. 2020, 9, e1117. DOI: 10.1002/cti2.1117

[29] Lin C, Smith C, Rutka J . Current immunotherapeutic approaches to diffuse intrinsic pontine glioma. Front. Genet. 2024, 15, 1349612. DOI: 10.3389/fgene.2024.1349612

[30] Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016, 534, 396-401. DOI: 10.1038/nature18300

[31] Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020, 585, 107-112. DOI: 10.1038/s41586-020-2537-9

[32] Miao L, Zhang Y, Huang L . mRNA vaccine for cancer immunotherapy. Mol. Cancer 2021, 20, 41. DOI: 10.1186/s12943-021-01335-5

[33] Shi J, Wang J, Luo H, Zhao Q, Yao Z, Wu G, et al. Neoantigen-based T cell vaccines design strategies, therapeutic barriers, and clinical advances. Vaccine 2026, 83, 128659. DOI: 10.1016/j.vaccine.2026.128659

[34] Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017, 547, 222-226. DOI: 10.1038/nature23003

[35] Wei J, Hui A-M . The paradigm shift in treatment from COVID-19 to oncology with mRNA vaccines. Cancer Treat. Rev. 2022, 107, 102405. DOI: 10.1016/j.ctrv.2022.102405

[36] Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. Lancet 2024, 403, 632-644. DOI: 10.1016/S0140-6736(23)02268-7

[37] Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023, 618, 144-150. DOI: 10.1038/s41586-023-06063-y

[38] Polack Fernando P, Thomas Stephen J, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603-2615. DOI: 10.1056/NEJMoa2034577

[39] Baden Lindsey R, El Sahly Hana M, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021, 384, 403-416. DOI: 10.1056/NEJMoa2035389

[40] Krawczyk PS, Mazur M, Orzeł W, Gewartowska O, Jeleń S, Antczak W, et al. Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines. Nature 2025, 641, 984-992. DOI: 10.1038/s41586-025-08842-1

[41] Soler S, Maser K, Zillinger T, Bartok E. To modify or not to modify-That is still the question for some mRNA applications. Mol. Ther. Nucleic Acids 2025, 36, 102655. DOI: 10.1016/j.omtn.2025.102655

[42] Tiwari HK, Gogoi-Tiwari J, Robertson ID . Eliminating dog-mediated rabies: Challenges and strategies. Anim. Dis. 2021, 1, 19. DOI: 10.1186/s44149-021-00023-7

[43] Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 2017, 390, 1511-1520. DOI: 10.1016/S0140-6736(17)31665-3

[44] Kwon H, Kim M, Seo Y, Moon YS, Lee HJ, Lee K, et al. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials 2018, 156, 172-193. DOI: 10.1016/j.biomaterials.2017.11.034

[45] Jahanafrooz Z, Baradaran B, Mosafer J, Hashemzaei M, Rezaei T, Mokhtarzadeh A, et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discov. Today 2020, 25, 552-560. DOI: 10.1016/j.drudis.2019.12.003

[46] Schmidt C, Schnierle BS. Self-amplifying RNA vaccine candidates: Alternative platforms for mRNA vaccine development. Pathogens 2023, 12, 138. DOI: 10.3390/pathogens12010138

[47] Okechukwu Paul-Chima U, Michael Ben O, Fabian CO, Jovita Nnenna U, Chinyere NU . Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: Progress, evidence gaps, and translational pathways for durable and scalable immunization. Hum. Vaccines Immunother. 2026, 22, 2661120. DOI: 10.1080/21645515.2026.2661120

[48] McGee JE, Kirsch JR, Kenney D, Cerbo F, Chavez EC, Shih T-Y, et al. Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency. Nat. Biotechnol. 2025, 43, 720-726. DOI: 10.1038/s41587-024-02306-z

[49] Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, et al. A Trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol. Ther. 2020, 28, 119-128. DOI: 10.1016/j.ymthe.2019.09.009

[50] Perkovic M, Gawletta S, Hempel T, Brill S, Nett E, Sahin U, et al. A trans-amplifying RNA simplified to essential elements is highly replicative and robustly immunogenic in mice. Mol. Ther. 2023, 31, 1636-1646. DOI: 10.1016/j.ymthe.2023.01.019

[51] Xie J, Ye F, Deng X, Tang Y, Liang J-Y, Huang X, et al. Circular RNA: A promising new star of vaccine. J. Transl. Intern. Med. 2023, 11, 372-381. DOI: 10.2478/jtim-2023-0122

[52] Liu C-X, Chen L-L . Circular RNAs: Characterization, cellular roles, and applications. Cell 2022, 185, 2016-2034. DOI: 10.1016/j.cell.2022.04.021

[53] An L, Li S, Zhang K . Structural insights and engineering of the T4 td intron for improved RNA circularization. Nat. Catal. 2025, 8, 1281-1294. DOI: 10.1038/s41929-025-01445-z

[54] Huang Y, Chen Y-Q, Lou S-Y, Gao X, Liu Y-X, Zhang Y-L, et al. IRES-cargo interplay structurally modulates circular RNA translation. Cell Res. 2026, 36, 377-380. DOI: 10.1038/s41422-026-01233-9

[55] Rokade S, Damani AM, Oft M, Emmerich J . IL-2 based cancer immunotherapies: An evolving paradigm. Front. Immunol. 2024, 15, 1433989. DOI: 10.3389/fimmu.2024.1433989

[56] Kim C, Lee Y, Lee H, Kim B-S . Advances in mRNA-lipid nanoparticle engineering for immune cell targeting and immune modulation. Small Methods 2025, 9, e01401. DOI: 10.1002/smtd.202501401

[57] Beck JD, Diken M, Suchan M, Streuber M, Diken E, Kolb L, et al. Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell 2024, 42, 568-582.e511. DOI: 10.1016/j.ccell.2024.02.013

[58] Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, et al. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J. ImmunoTherapy Cancer 2018, 6, 125. DOI: 10.1186/s40425-018-0431-x

[59] Hewitt SL, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, et al. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment. Clin. Cancer Res. 2020, 26, 6284-6298. DOI: 10.1158/1078-0432.CCR-20-0472

[60] Hewitt SL, Bai A, Bailey D, Ichikawa K, Zielinski J, Karp R, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci. Transl. Med. 2019, 11, eaat9143. DOI: 10.1126/scitranslmed.aat9143

[61] Jansen Y, Kruse V, Corthals J, Schats K, van Dam P-J, Seremet T, et al. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol. Immunother. 2020, 69, 2589-2598. DOI: 10.1007/s00262-020-02618-4

[62] Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat. Med. 2017, 23, 815-817. DOI: 10.1038/nm.4356

[63] Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, et al. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo . Mol. Ther. 2019, 27, 1415-1423. DOI: 10.1016/j.ymthe.2019.05.012

[64] Wu L, Wang W, Tian J, Qi C, Cai Z, Yan W, et al. Intravenous delivery of RNA encoding anti-PD-1 human monoclonal antibody for treating intestinal cancer. J. Cancer 2022, 13, 579-588. DOI: 10.7150/jca.63991

[65] Huang C, Duan X, Wang J, Tian Q, Ren Y, Chen K, et al. Lipid nanoparticle delivery system for mRNA encoding B7H3-redirected bispecific antibody displays potent antitumor effects on malignant tumors. Adv. Sci. 2023, 10, 2205532. DOI: 10.1002/advs.202205532

[66] Lee Y-R, Chen M, Pandolfi PP . The functions and regulation of the PTEN tumour suppressor: New modes and prospects. Nat. Rev. Mol. Cell Biol. 2018, 19, 547-562. DOI: 10.1038/s41580-018-0015-0

[67] Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat. Biomed. Eng. 2018, 2, 850-864. DOI: 10.1038/s41551-018-0284-0

[68] Lin Y-X, Wang Y, Ding J, Jiang A, Wang J, Yu M, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci. Transl. Med. 2021, 13, eaba9772. DOI: 10.1126/scitranslmed.aba9772

[69] Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, et al. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci. Transl. Med. 2019, 11, eaaw1565. DOI: 10.1126/scitranslmed.aaw1565

[70] Zhou H, Liao Y, Han X, Chen DS, Hong X, Zhou K, et al. ROS-responsive nanoparticle delivery of mRNA and photosensitizer for combinatorial cancer therapy. Nano Lett. 2023, 23, 3661-3668. DOI: 10.1021/acs.nanolett.2c03784

[71] Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL . Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 2021, 21, 382-393. DOI: 10.1038/s41577-021-00542-x

[72] Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 2020, 583, 290-295. DOI: 10.1038/s41586-020-2349-y

[73] Tiwari PM, Vanover D, Lindsay KE, Bawage SS, Kirschman JL, Bhosle S, et al. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat. Commun. 2018, 9, 3999. DOI: 10.1038/s41467-018-06508-3

[74] Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. 2019, 4, eaaw6647. DOI: 10.1126/sciimmunol.aaw6647

[75] Erasmus JH, Archer J, Fuerte-Stone J, Khandhar AP, Voigt E, Granger B, et al. Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika Virus infection. Mol. Ther. -Methods Clin. Dev. 2020, 18, 402-414. DOI: 10.1016/j.omtm.2020.06.011

[76] Song Y, Li J, Wu Y . Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. Signal Transduct. Target. Ther. 2024, 9, 263. DOI: 10.1038/s41392-024-01952-8

[77] Berry CT, Frazee CS, Herman PJ, Chen S, Chen A, Kuo Y, et al. Current advancements in cellular immunotherapy for autoimmune disease. Semin. Immunopathol. 2025, 47, 7. DOI: 10.1007/s00281-024-01034-5

[78] Savguira M, Chen DXW, Dong S, Li B . RNA immunotherapy: Revolutionizing cancer and autoimmune disease treatments. Trends Mol. Med. 2026, 32, 181-196. DOI: 10.1016/j.molmed.2025.06.008

[79] Zhou H, Wei D, Chen Z, Chen H, Dong C, Yao W, et al. The mRNA-based innovative strategy: Progress and challenges. Nano-Micro Lett. 2026, 18, 118. DOI: 10.1007/s40820-025-01906-x

[80] Baek R, Coughlan K, Jiang L, Liang M, Ci L, Singh H, et al. Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria. Nat. Commun. 2024, 15, 3804. DOI: 10.1038/s41467-024-47460-9

[81] Koeberl D, Schulze A, Sondheimer N, Lipshutz GS, Geberhiwot T, Li L, et al. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. Nature 2024, 628, 872-877. DOI: 10.1038/s41586-024-07266-7

[82] Perez-Garcia CG, Diaz-Trelles R, Vega JB, Bao Y, Sablad M, Limphong P, et al. Development of an mRNA replacement therapy for phenylketonuria. Mol. Ther. Nucleic Acids 2022, 28, 87-98. DOI: 10.1016/j.omtn.2022.02.020

[83] McNutt M, Vockley J, Zori R, Basel D, Breilyn M, Longo N, et al. IT translates: An update on the ARCT-810 mRNA therapy for OTC deficiency. Mol. Genet. Metab. 2024, 141, 108161. DOI: 10.1016/j.ymgme.2024.108161

[84] Zhou Z, Chen W, Yu H, Tabas I, Foo RSY, Tao W . mRNA medicine for cardiovascular disease. Nat. Cardiovasc. Res. 2026, 5, 291-307. DOI: 10.1038/s44161-026-00804-8

[85] Wang R, Zhang R, Zhou J, Ran J . Crosstalk between anti-angiogenic and pro-angiogenic pathways in disease: Mechanisms and therapeutic strategies. Pharmacol. Ther. 2025, 276, 108934. DOI: 10.1016/j.pharmthera.2025.108934

[86] Gan L-M, Lagerström-Fermér M, Carlsson LG, Arfvidsson C, Egnell A-C, Rudvik A, et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nat. Commun. 2019, 10, 871. DOI: 10.1038/s41467-019-08852-4

[87] Anttila V, Saraste A, Knuuti J, Hedman M, Jaakkola P, Laugwitz K-L, et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol. Ther. 2023, 31, 866-874. DOI: 10.1016/j.ymthe.2022.11.017

[88] Singh RN, Horn MM, Juko M, Kampshoff A, Schmid J, Omran H, et al. Restoration of defective CFTR in human nasal respiratory epithelial cells by CFTR modulators and mRNA transfection. Int. J. Mol. Sci. 2026, 27, 2063. DOI: 10.3390/ijms27042063

[89] Robinson E, MacDonald KD, Slaughter K, McKinney M, Patel S, Sun C, et al. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol. Ther. 2018, 26, 2034-2046. DOI: 10.1016/j.ymthe.2018.05.014

[90] Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, et al. Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J. Cyst. Fibros. 2023, 22, 656-664. DOI: 10.1016/j.jcf.2023.04.008

[91] Makarova KS, Shmakov SA, Wolf YI, Mutz P, Altae-Tran H, Beisel CL, et al. An updated evolutionary classification of CRISPR-Cas systems including rare variants. Nat. Microbiol. 2025, 10, 3346-3361. DOI: 10.1038/s41564-025-02180-8

[92] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337, 816-821. DOI: 10.1126/science.1225829

[93] Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK . Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 2014, 32, 279-284. DOI: 10.1038/nbt.2808

[94] Rozners E. Chemical modifications of CRISPR RNAs to improve gene-editing activity and specificity. J. Am. Chem. Soc. 2022, 144, 12584-12594. DOI: 10.1021/jacs.2c02633

[95] Rahdar M, McMahon MA, Prakash TP, Swayze EE, Bennett CF, Cleveland DW . Synthetic CRISPR RNA-Cas9-guided genome editing in human cells. Proc. Natl. Acad. Sci. 2015, 112, E7110-E7117. DOI: 10.1073/pnas.1520883112

[96] Barber HM, Pater AA, Gagnon KT, Damha MJ, O’Reilly D . Chemical engineering of CRISPR-Cas systems for therapeutic application. Nat. Rev. Drug Discov. 2025, 24, 209-230. DOI: 10.1038/s41573-024-01086-0

[97] Yin H, Song C-Q, Suresh S, Wu Q, Walsh S, Rhym LH, et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing . Nat. Biotechnol. 2017, 35, 1179-1187. DOI: 10.1038/nbt.4005

[98] Wang H-X, Li M, Lee CM, Chakraborty S, Kim H-W, Bao G, et al. CRISPR/Cas9-based genome editing for disease modeling and therapy: Challenges and opportunities for nonviral delivery. Chem. Rev. 2017, 117, 9874-9906. DOI: 10.1021/acs.chemrev.6b00799

[99] Li W, Wang C, Lu Y . When mRNA meets gene editing. Nano Res. 2024, 17, 7337-7356. DOI: 10.1007/s12274-024-6729-8

[100] Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 2020, 6, eabc9450. DOI: 10.1126/sciadv.abc9450

[101] Kim M, Song ES, Chen JC, Chatterjee S, Sun Y, Lee SM, et al. Dual SORT LNPs for multi-organ base editing. Nat. Biotechnol. 2026, 44, 578-586. DOI: 10.1038/s41587-025-02675-z

[102] Farbiak L, Cheng Q, Wei T, Álvarez-Benedicto E, Johnson LT, Lee S, et al. All-in-one dendrimer-based lipid Nanoparticles enable precise HDR-mediated gene editing in vivo . Adv. Mater. 2021, 33, 2006619. DOI: 10.1002/adma.202006619

[103] Xu L, Yang H, Gao Y, Chen Z, Xie L, Liu Y, et al. CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo . Mol. Ther. 2017, 25, 1782-1789. DOI: 10.1016/j.ymthe.2017.04.027

[104] Xu L, Wang J, Liu Y, Xie L, Su B, Mou D, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 2019, 381, 1240-1247. DOI: 10.1056/NEJMoa1817426

[105] Mancuso P, Chen C, Kaminski R, Gordon J, Liao S, Robinson JA, et al. CRISPR based editing of SIV proviral DNA in ART treated non-human primates. Nat. Commun. 2020, 11, 6065. DOI: 10.1038/s41467-020-19821-7

[106] Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 2018, 559, 405-409. DOI: 10.1038/s41586-018-0326-5

[107] Gillmore Julian D, Gane E, Taubel J, Kao J, Fontana M, Maitland Michael L, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis . N. Engl. J. Med. 2021, 385, 493-502. DOI: 10.1056/NEJMoa2107454

[108] Cohn Danny M, Gurugama P, Magerl M, Katelaris Constance H, Launay D, Bouillet L, et al. CRISPR-based therapy for hereditary angioedema. N. Engl. J. Med. 2025, 392, 458-467. DOI: 10.1056/NEJMoa2405734

[109] Han JP, Kim M, Choi BS, Lee JH, Lee GS, Jeong M, et al. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Sci. Adv. 2022, 8, eabj6901. DOI: 10.1126/sciadv.abj6901

[110] Qi C, Fan D, Wang L, Guo L, Jiang H, Wang L . Mechanisms of action and therapeutic potential of PCSK9-regulating drugs. Pharm. Biol. 2025, 63, 428-446. DOI: 10.1080/13880209.2025.2514021

[111] Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 2021, 593, 429-434. DOI: 10.1038/s41586-021-03534-y

[112] Laffin Luke J, Nicholls Stephen J, Scott Russell S, Clifton Peter M, Baker J, Sarraju A, et al. Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. N. Engl. J. Med. 2025, 393, 2119-2130. DOI: 10.1056/NEJMoa2511778

[113] Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature 2019, 573, 430-433. DOI: 10.1038/s41586-019-1546-z

[114] Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, et al. CAR T cells producedin vivo to treat cardiac injury. Science 2022, 375, 91-96. DOI: 10.1126/science.abm0594

[115] Hou X, Zaks T, Langer R, Dong Y . Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021, 6, 1078-1094. DOI: 10.1038/s41578-021-00358-0

[116] Kim J, Jozic A, Lin Y, Eygeris Y, Bloom E, Tan X, et al. Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation. ACS Nano 2022, 16, 14792-14806. DOI: 10.1021/acsnano.2c05647

[117] Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZC, Rotolo L, Echeverri ES, et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 2021, 5, 1059-1068. DOI: 10.1038/s41551-021-00786-x

[118] Liu S, Wen Y, Shan X, Ma X, Yang C, Cheng X, et al. Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination. Nat. Commun. 2024, 15, 9471. DOI: 10.1038/s41467-024-53914-x

[119] Jiang AY, Lathwal S, Meng S, Witten J, Beyer E, McMullen P, et al. Zwitterionic Polymer-Functionalized Lipid Nanoparticles for the Nebulized Delivery of mRNA. J. Am. Chem. Soc. 2024, 146, 32567-32574. DOI: 10.1021/jacs.4c11347

[120] Lei J, Yang K, Cao W, Qi S, Du X, Li H, et al. Pancreatic-targeted lipid nanoparticles based on organ capsule filtration. Nature 2026, 652, 220-229. DOI: 10.1038/s41586-026-10158-7

[121] Qiu X, Yang Y, Ma Q, Zheng B, Chen Z, Wu F, et al. Thioketal-Incorporated Biodegradable Lipid Nanoparticles Deliver mRNA to Ductal Epithelial Cells for Improved Pancreatic Cancer Treatment. J. Am. Chem. Soc. 2025, 147, 44605-44616. DOI: 10.1021/jacs.5c19387

[122] Youn K, Oh S, Gil H, Choi Y, Keum G, Bang E-K. Delivery strategies of messenger RNA therapeutics for brain disorders. Bull. Korean Chem. Soc. 2025, 46, 1186-1204. DOI: 10.1002/bkcs.70083

[123] Yu X, Deng X-M, Lin Y, Ren H, Jia L, Meng Y, et al. Nose-to-Brain Delivery of mRNA-Loaded Lipid Nanoparticles Bypasses the Blood-Brain Barrier for Effective Brain Disease Therapy. ACS Nano 2026, 20, 15589-15605. DOI: 10.1021/acsnano.6c04580

[124] García-González N, Gonçalves-Sánchez J, Gómez-Nieto R, Gonçalves-Estella JM, López DE . Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review. Int. J. Mol. Sci. 2024, 25, 12485. DOI: 10.3390/ijms252312485

[125] Xue Y, Wang C, Li H, Du S, Zhong Y, Zhang Y, et al. Lipid Nanoparticles Enhance mRNA Delivery to the Central Nervous System Upon Intrathecal Injection. Adv. Mater. 2025, 37, 2417097. DOI: 10.1002/adma.202417097

[126] Han EL, Tang S, Kim D, Murray AM, Swingle KL, Hamilton AG, et al. Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain. Nano Lett. 2024, 25, 800-810. DOI: 10.1021/acs.nanolett.4c05186

[127] Geisler HC, Ghalsasi AA, Safford HC, Swingle KL, Thatte AS, Mukalel AJ, et al. EGFR-targeted ionizable lipid nanoparticles enhance in vivo mRNA delivery to the placenta. J. Control. Release 2024, 371, 455-469. DOI: 10.1016/j.jconrel.2024.05.036

[128] Chen MZ, Yuen D, McLeod VM, Yong KW, Smyth CH, Herling BR, et al. A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles . Nat. Nanotechnol. 2025, 20, 1273-1284. DOI: 10.1038/s41565-025-01954-9

[129] Shah S, Ranasinghe M, Decker J, Fraser K, Wang Y, Kinlaw S, et al. Lipid nanoparticles with aptamers enable targeted mRNA delivery to CD4⁺ T cells. Drug Deliv. 2026, 33, 2637266. DOI: 10.1080/10717544.2026.2637266

[130] Li J, Yu J, Song J, Zhang Y, Li N, Wang Z, et al. Galloylated liposomes enable targeted drug delivery by overcoming protein corona shielding. Nat. Commun. 2025, 16, 7926. DOI: 10.1038/s41467-025-63198-4

[131] Wang Z, Zhang J, Wang Y, Zhou J, Jiao X, Han M, et al. Overcoming Endosomal Escape Barriers in Gene Drug Delivery Using De Novo Designed pH-Responsive Peptides. ACS Nano 2024, 18, 10324-10340. DOI: 10.1021/acsnano.4c02400

[132] Deng X, Li Y, Zhu X, Du Y, Chi H, Cheng M, et al. pH-Isomerizable Acylhydrazone-Based Ionizable Lipids for Spleen-Targeted mRNA Vaccines. J. Am. Chem. Soc. 2025, 147, 47428-47442. DOI: 10.1021/jacs.5c16121

[133] Chen Z, Yang Y, Qiu X, Zhou H, Wang R, Xiong H . Crown-like Biodegradable Lipids Enable Lung-Selective mRNA Delivery and Dual-Modal Tumor Imaging In Vivo . J. Am. Chem. Soc. 2024, 146, 34209-34220. DOI: 10.1021/jacs.4c14500

[134] Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ . Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 2020, 15, 313-320. DOI: 10.1038/s41565-020-0669-6

[135] Dilliard SA, Cheng Q, Siegwart DJ . On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl. Acad. Sci. USA 2021, 118, e2109256118. DOI: 10.1073/pnas.2109256118

[136] Wang X, Tian Z, Pacheco Benitez A, Bian X, Vaidya A, Guerrero E, et al. Tunable polymers for polymer-lipid hybrid nanoparticles facilitate controlled organ-selective RNA delivery. Nat. Chem. Eng. 2026. DOI: 10.1038/s44286-026-00425-9

[137] Nie X, Liu Y, Song Y, Yao X, Chen Y, Lee H-Y, et al. In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy. Sci. Transl. Med. 2025, 18, eady6730. DOI: 10.1126/scitranslmed.ady6730

[138] Huang X, Liu C, Sharma SN, You X, Chen S, Li Y, et al. Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease. Sci. Transl. Med. 2025, 17, eadu1493. DOI: 10.1126/scitranslmed.adu1493

[139] Zhao H, Xu J, Gao X, Zhu J, He Z . Artificial intelligence in the rational design of lipid nanoparticles for mRNA therapeutics. Innov. Drug Discov. 2026, 1, 100006. DOI: 10.59717/j.xinn-drugdisc.2026.100006

[140] Su K, Qiu J, Xu T, Liu S . Artificial intelligence-guided design of lipid nanoparticles for mRNA delivery. Acta Pharm. Sin. B 2026, 16, 709-727. DOI: 10.1016/j.apsb.2025.11.029

[141] Yang B, Liu J, Li Y, Liu X . mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics. Cancer Innov. 2025, 4, e70041. DOI: 10.1002/cai2.70041

[142] Que J, Xue G, Wang T, Jin X, Wang Z, Cai Y, et al. Identifying T cell antigen at the atomic level with graph convolutional network. Nat. Commun. 2025, 16, 5171. DOI: 10.1038/s41467-025-60461-6

[143] Zhao Y, Yu J, Su Y, Shu Y, Ma E, Wang J, et al. A unified deep framework for peptide-major histocompatibility complex-T cell receptor binding prediction. Nat. Mach. Intell. 2025, 7, 650-660. DOI: 10.1038/s42256-025-01002-0

[144] Xiong Y, Wang A, Kang Y, Shen C, Hsieh C-Y, Hou T . mRNABERT: Advancing mRNA sequence design with a universal language model and comprehensive dataset. Nat. Commun. 2025, 16, 10371. DOI: 10.1038/s41467-025-65340-8

[145] Rajbanshi B, Guruacharya A . codonGPT: Reinforcement learning on a generative language model enables scalable mRNA design. Nucleic Acids Res. 2025, 53, gkaf1345. DOI: 10.1093/nar/gkaf1345

[146] Zhang H, Liu H, Xu Y, Huang H, Liu Y, Wang J, et al. Deep generative models design mRNA sequences with enhanced translational capacity and stability. Science 2025, 390, eadr8470. DOI: 10.1126/science.adr8470

[147] Zeng J, Chen R, He S, Zhang C, Liu W-C, Song H, et al. High-throughput, AI-assisted design and optimization of lipid nanoparticles for drug delivery. J. Control. Release 2026, 391, 114573. DOI: 10.1016/j.jconrel.2025.114573

[148] Witten J, Raji I, Manan RS, Beyer E, Bartlett S, Tang Y, et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat. Biotechnol. 2025, 43, 1790-1799. DOI: 10.1038/s41587-024-02490-y.

[149] Xu Y, Ma S, Cui H, Chen J, Xu S, Gong F, et al. AGILE platform: A deep learning powered approach to accelerate LNP development for mRNA delivery. Nat. Commun. 2024, 15, 6305. DOI: 10.1038/s41467-024-50619-z

[150] Xu Y, Cui H, Pang K, Li G, Gong F, Dong S, et al. LUMI-lab: A foundation model-driven autonomous platform enabling discovery of ionizable lipid designs for mRNA delivery. Cell 2026, 189, 1620-1635.e1625. DOI: 10.1016/j.cell.2026.01.012

[151] Longhurst Hilary J, Lindsay K, Petersen Remy S, Fijen Lauré M, Gurugama P, Maag D, et al. CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema . N. Engl. J. Med. 2024, 390, 432-441. DOI: 10.1056/NEJMoa2309149

[152] Howard JF . Descartes-08: Unlocking the potential of mRNA CAR T-cell therapy in myasthenia gravis. Mol. Ther. 2026, 34, 2561-2563. DOI: 10.1016/j.ymthe.2026.04.008

[153] de Picciotto S, DeVita N, Hsiao CJ, Honan C, Tse S-W, Nguyen M, et al. Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein. Nat. Commun. 2022, 13, 3866. DOI: 10.1038/s41467-022-31130-9